Telix expects FY 2026 revenue, other income above US$1 billion, tracks upper end of guidance

Reuters2026/07/20 23:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Telix forecast FY 2026 revenue and other income above US$1 billion.
Revenue outlook tracking near the upper end of US$950 million to US$970 million, supported by a US$40 million non-refundable Regeneron payment.
Q2 group revenue reached US$247 million, up 7% QoQ, up 21% YoY; Precision Medicine revenue was US$202 million, up 9% QoQ.
FY 2026 R&D spend guidance lifted to US$230 million to US$270 million, enabled by commercial performance and the Regeneron payment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607201931PRIMZONEFULLFEED9765216) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Telix expects FY 2026 revenue, other income above US$1 billion, tracks upper end of guidance

You may also like

Crypto prices